BusinessResearch on Fetal Sex Differences in Predicting Spontaneous Preterm Birth Using Sera’s Proteomic Technology to be Presented at The 64th Annual Society for Reproductive Investigation MeetingBy Nasdaq OMXMar 13, 2017, 6:00 PM UTC
BusinessResearch on Underlying Mechanisms of Pregnancy Complications and Medical Interventions Using Sera’s Proteomic Technology to be Presented at the Society for Maternal-Fetal Medicine’s 37th Annual Pregnancy MeetingBy Nasdaq OMXJan 23, 2017, 8:09 PM UTC
BusinessSera Prognostics Enters into Agreement with LabCorp to be the Exclusive U.S. Distributor of PreTRM® TestBy Nasdaq OMXJan 10, 2017, 12:01 PM UTC
BusinessSera Prognostics Enters into Agreement with LabCorp to be the Exclusive U.S. Distributor of PreTRM® TestBy Nasdaq OMXJan 10, 2017, 12:01 PM UTC
BusinessTwo Peer-Reviewed Publications Highlight Clinical Utility of PreTRM® TestBy Nasdaq OMXDec 19, 2016, 2:00 PM UTC
BusinessSera Prognostics to Present at Ladenburg Thalmann 2016 Healthcare ConferenceBy Nasdaq OMXSep 20, 2016, 3:36 PM UTC
BusinessLandmark Study Published in American Journal of Obstetrics & Gynecology Validates New Blood Test as Objective, Predictive Tool for Preterm Birth RiskBy Nasdaq OMXMar 10, 2016, 12:00 PM UTC
